Skip to main content

April 2010

 

Clinical courses

Manage manufacturing activity in Alembic as Production Manager

Alembic Limited, with an established presence in the Indian pharma industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs1000 crores today, Alembic Limited is one of India’s leading integrated pharmaceutical companies. We continue to enjoy leadership positions in antibiotics, anti-infective, anti-cough and also have significant worldwide presence in specialty therapeutic areas such as cardiology, neurology, diabetology, etc.

State FDA lists 44 drug samples as not-of-standard drugs in March

Maharashtra Food and Drug Administration (FDA) has found 44 drugs not-of-standard-quality during its inspection in March 2010. Most of the not-of-standard-quality drugs were from tax-holiday states Himachal Pradesh and Uttaranchal. And every month, the number of sub-standard drug samples keeps increasing and firms from these two states have major share in this list.

Work for vaccine production started in 2 PSUs, BCG Lab in Chennai yet to get green signal

Even as two of the three PSUs, CRI in Kasauli and PII in Coonoor, have run into action within two months of accepting the order of resumption of vaccine production from the Union Health Ministry on February 26 this year, the BCG Vaccine Lab in Chennai is still waiting for approval from authorities to commence operations, it is learnt.

Glenmark's oral contraceptive gets FDA nod

Glenmark's US subsidiary Glenmark Generics has been granted approval by the United States Food and Drug Administration (FDA) for Norethindrone tablets 0.35mg—its generic version of Nor-QD. The product will be marketed under the trade name Heather and distribution is expected to start immediately.

AIIMS to conduct conference on care of children born with cleft lip, palate & craniofacial anomalies

The All India Institute of Medical Sciences (AIIMS), New Delhi is hosting a conference on the care of children born with cleft lip, palate and craniofacial anomalies. The programme is part of the ninth Annual Conference of the Indian Society of Cleft Lip palate and Craniofacial Anomalies which is being held in New Delhi from April 23 to April 25.

Indian pharma companies will become product companies, Reinhard Gluck, Cadila, India

The foremost challenge for any pharma company with biotech divisions or units in the Asian region is bringing out the product. We do not have too many products. However, I have been convinced that at least some Indian companies will do it.

Liraglutide Superior to Sitagliptin When Added to Metformin for Glycemic Control

The addition of a glucagonlike peptide-1 (GLP-1) agonist in patients with inadequate glycemic control when treated with metformin alone resulted in significantly larger reductions in HbA1c levels when compared with the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor, a new study has shown.

FDA Launches Campaign to Improve Infusion-Pump Safety

The US Food and Drug Administration (FDA) today unveiled an ambitious campaign to improve the safety of external infusion pumps, which have triggered 56,000 FDA adverse event reports linked to more than 500 deaths and 87 product recalls from 2005 through 2009, according to the agency.

The campaign mostly affects the makers of external infusion pumps, which may find FDA inspectors visiting their plants to ensure that safe manufacturing and testing processes are in place.

Vacancy for the post of Research Associate - R&D / F&D at Panacea Biotech | Freshers can also apply.

Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.We offer stimulating work environment & a career that spells growth.